ストックスクリーナーアプリを入手
4.23
1.20%
0.05
アフターアワーズ：
4.09
-0.14
-3.31%
前日終値:
$4.18
開ける：
$4.18
24時間の取引高:
982.83K
Relative Volume:
0.85
時価総額：
$524.00M
収益：
$69.56M
当期純損益:
$-240.05M
株価収益率:
-1.4339
EPS:
-2.95
ネットキャッシュフロー:
$-121.90M
1週間 パフォーマンス:
+28.57%
1か月 パフォーマンス:
+4.44%
6か月 パフォーマンス:
+15.26%
1年 パフォーマンス:
+113.64%
1日の値動き範囲:
$4.09
$4.32
1週間の範囲:
$3.15
$4.32
52週間の値動き範囲:
$1.05
$4.80
Adc Therapeutics Sa Stock (ADCT) Company Profile
ADCT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
4.23 | 517.81M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-08 | 開始されました | Stephens | Overweight |
| 2024-05-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-03-28 | 開始されました | Guggenheim | Buy |
| 2023-08-10 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-04-24 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-12-06 | 開始されました | CapitalOne | Overweight |
| 2022-11-09 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-09-21 | 開始されました | JP Morgan | Overweight |
| 2022-09-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | 開始されました | Wolfe Research | Outperform |
| 2021-08-17 | 再開されました | Jefferies | Buy |
| 2021-08-09 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-06-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-12-03 | 開始されました | Stifel | Hold |
| 2020-10-29 | 開始されました | H.C. Wainwright | Buy |
| 2020-06-09 | 開始されました | BofA/Merrill | Buy |
| 2020-06-09 | 開始されました | Cowen | Outperform |
すべてを表示
Adc Therapeutics Sa (ADCT) 最新ニュース
ADC Therapeutics SA Stock Analysis and ForecastHigh Beta Stocks & Predict Price Movements With AI Precision - earlytimes.in
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SAADCT - PR Newswire
Adc Therapeutics SA (ADCT) expanding its growth trajectory ahead - setenews.com
ADC Therapeutics reports promising LOTIS-7 trial results - MSN
Is ADC Therapeutics SA a good long term investmentCup and Handle Formations & Discover High-Return Stocks Before They Boom - earlytimes.in
Will Fed Rate Hikes Affect Voltaire Leasing Finance Limited Stocks OutlookPrice Volatility Patterns & Target Triple-Digit Stock Opportunities - earlytimes.in
ADC Therapeutics Reports Promising LOTIS-7 Trial Results - TipRanks
ADC Therapeutics Updates LOTIS-7 Trial Data - TradingView
[8-K] ADC Therapeutics SA Reports Material Event | ADCT SEC FilingForm 8-K - Stock Titan
Is ADC Therapeutics SA Common Shares stock attractive post correction2025 Institutional Moves & Growth Focused Investment Plans - Newser
Is ADC Therapeutics SA stock oversold or undervalued2025 Market WrapUp & Scalable Portfolio Growth Ideas - Newser
What momentum indicators show for ADC Therapeutics SA stockShare Buyback & Accurate Entry and Exit Point Alerts - Newser
Will ADC Therapeutics SA stock benefit from commodity pricesQuarterly Trade Summary & Daily Entry Point Alerts - Newser
How forex fluctuations impact ADC Therapeutics SA Common Shares stockPortfolio Performance Report & Reliable Intraday Trade Plans - Newser
Will ADC Therapeutics SA Common Shares stock boost dividends further2025 Analyst Calls & Capital Protection Trading Alerts - Newser
Can ADC Therapeutics SA stock deliver surprise earnings beatOptions Play & Long-Term Investment Growth Plans - Newser
Why Is ADC Therapeutics Plunging Today - Sahm
Snowflake, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma - Yahoo Finance
ADC Therapeutics (NYSE:ADCT) Trading Up 6.5%Should You Buy? - MarketBeat
ADC Therapeutics stock falls after LOTIS-7 trial update By Investing.com - Investing.com Canada
ADC Therapeutics stock falls after LOTIS-7 trial update - Investing.com India
Crude Oil Gains 1%; Macy's Reports Strong Q3 Results - Benzinga
ZYNLONTA-glofitamab combo shows 90% response rate in lymphoma trial By Investing.com - Investing.com Nigeria
ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCLSlideshow (NYSE:ADCT) 2025-12-03 - Seeking Alpha
ADCT: LOTIS-7: Zynlonta plus glofitamab delivers high, durable CR rates and manageable safety in DLBCL - TradingView
ADC Therapeutics : (ADCT Webcast Presentation 120225) - marketscreener.com
ADC Therapeutics Says Updated Data for Drug Supports Potential Best-in-Class Regimen in Lymphoma Patients - marketscreener.com
ADCT: ZYNLONTA plus glofitamab delivers high response rates and manageable safety in r/r LBCL - TradingView
ZYNLONTA-glofitamab combo shows 90% response rate in lymphoma trial - Investing.com
ADC Therapeutics announces updated data from Lotis-7 phase 1b clinical trial of Zynlonta - marketscreener.com
Adc Therapeutics Announces Updated Data From Lotis-7 Phase 1B Clinical Trial Of Zynlonta - TradingView
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma - Fidelity
ADCT: LOTIS-7 Phase 1b trial update for ZYNLONTA plus glofitamab in r/r DLBCL set for Dec 3, 2025 - TradingView
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial - BioSpace
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - 富途牛牛
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year? - sharewise.com
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) - Aktiellt
H.C. Wainwright Lowers ADC Therapeutics (ADCT) PT to $7 Following $60M Private Placement - MSN
Adc Therapeutics Sa (ADCT) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):